2 Sources
[1]
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Indivior, CrowdStrike, DXC, and Five Below and Encourages Investors to Contact the Firm - CrowdStrike Holdings (NASDAQ:CRWD), DXC Technology (NYSE:DXC)
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Indivior PLC INDV, CrowdStrike Holdings, Inc. CRWD, DXC Technology Company DXC, and
[2]
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Symbotic, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm - Extreme Networks (NASDAQ:EXTR), Sprinklr (NYSE:CXM)
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Symbotic Inc. SYM, PDD Holdings Inc. PDD, Extreme Networks, Inc. EXTR, and Sprinklr,
Share
Copy Link
Bragar Eagel & Squire, P.C. announces class action lawsuits against several companies including Symbotic Inc., Infinity Pharmaceuticals, Inc., and Enviva Inc. The law firm urges affected investors to join the suits before upcoming deadlines.

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, has announced that class action lawsuits have been filed against several companies, including Symbotic Inc. (NASDAQ: SYM), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), and Enviva Inc. (NYSE: EVA). The firm is urging investors who purchased securities during specific periods to come forward and potentially serve as lead plaintiffs in these cases
1
2
.The class action lawsuit against Symbotic Inc. covers investors who acquired securities between January 13, 2022, and March 13, 2023. The complaint alleges that the company made materially false and misleading statements regarding its business operations and prospects. Specifically, Symbotic is accused of overstating its earnings, cash, and accounts receivable, while understating its losses
1
.Infinity Pharmaceuticals faces a lawsuit concerning investors who purchased securities between January 5, 2022, and July 24, 2023. The company is alleged to have made false and/or misleading statements about its MARIO-4 Phase 3 clinical trial and the viability of its lead product candidate, eganelisib
2
.The class action against Enviva Inc. involves investors who acquired securities between November 3, 2022, and May 3, 2023. The lawsuit claims that Enviva made materially false and/or misleading statements and failed to disclose material adverse facts about its operations, business, and prospects
1
.Bragar Eagel & Squire emphasizes that class action lawsuits have already been filed against these companies. The firm is encouraging affected investors to contact them to discuss their legal rights and options. It's important to note that under federal securities laws, investors have the right to seek recovery of their losses
1
2
.Related Stories
The law firm has highlighted several important deadlines for investors who wish to be considered for the role of lead plaintiff:
Investors are urged to contact the firm before these deadlines to explore their legal options
1
2
.Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm and its attorneys, please visit www.bespc.com
1
2
.These class action lawsuits underscore the importance of corporate transparency and the rights of investors to seek redress when they believe they have been misled. As these cases progress, they may have significant implications for the companies involved and their shareholders.
Summarized by
Navi
31 Aug 2024

13 Aug 2024

22 Aug 2024

1
Technology

2
Technology

3
Policy and Regulation
